Sign in

CIK 0001737953 · Non-accelerated filer<br>Smaller reporting company

Replimune Group, Inc.

Sign in to watch
Ticker
REPL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Mar 31
Incorporated
DE
Entity type
operating
EIN
822082553
Phone
(781) 222-9600
Business address
500 UNICORN PARK, WOBURN, MA, 01801
  1. 4 Open-market sale Chief Medical Officer sold 7,248 shares at $9.10 ($65,957)
  2. 4 Open-market sale Chief Financial Officer sold 9,154 shares at $5.37 ($49,157)
  3. 4 Open-market sale Director sold 32,279 shares at $8.06 ($260,169)
  4. 4 Open-market sale Chief Medical Officer sold 7,952 shares at $8.06 ($64,093)
  5. 4 Open-market sale Chief Accounting Officer sold 3,287 shares at $8.05 ($26,460)
  6. 4 Open-market sale Chief Executive Officer sold 25,105 shares at $8.06 ($202,346)
  7. 4 Open-market sale Chief Financial Officer sold 2,535 shares at $8.05 ($20,407)
  8. 4 Open-market sale Chief Commercial Officer sold 3,749 shares at $8.05 ($30,179)
  9. 4 Derivatives Options or other derivatives
  10. 4 Grant or award Chief Executive Officer acquired 166,667 shares (grant or award)
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Grant or award Chief Medical Officer acquired 45,000 shares (grant or award)
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Grant or award Chief Financial Officer acquired 45,000 shares (grant or award)
  17. 4 Derivatives Options or other derivatives
  18. 4 Grant or award Chief Commercial Officer acquired 45,000 shares (grant or award)
  19. 4 Derivatives Options or other derivatives
  20. 4 Grant or award Chief Accounting Officer acquired 33,333 shares (grant or award)

Page 3 of 16 · 316 filings